Altogether, these results demonstrate that AlloCAR70-NKT cells possess a dual capacity to target both RCC tumor cells and the immunosuppressive TME by eliminating CD1d+ TAMs and MDSCs. Here, CD1D is linked to renal cell carcinoma.